A Post-Authorisation Safety Study of the Utilisation and Prescribing Patterns of Xeljanz® (tofacitinib) Using an Administrative Healthcare Database in FranceFirst published 09/08/2024 Last updated 04/06/2025 EU PAS number: EUPAS1000000247StudyOngoing
Evidence and Access/Analytica Laser, CertaraFranceUnited Kingdom (Northern Ireland) First published: 24/05/2021Last updated 06/03/2024 InstitutionNon-Pharmaceutical companyENCePP partner